Table 1 Participant characteristics (n = 11)
From: Daily variations of gut microbial translocation markers in ART-treated HIV-infected people
ID | Age | Body mass index(kg/m2) | CD4 count (cells/µL) | CD8 counts (cells/µL) | ART duration (years) | Viral load | Current ART medication |
|---|---|---|---|---|---|---|---|
1 | 60 | 27.8 | 602 | 1321 | 10 | Undetectable | Emtricitabine, TDF, raltegravir |
2 | 52 | 27.1 | 491 | 613 | 21 | Undetectable | Emtricitabine, TDF, raltegravir |
3 | 57 | 28.4 | 606 | 855 | 12 | Undetectable | Emtricitabine, TDF, raltegravir |
4 | 57 | 32.9 | 846 | 901 | 22 | Undetectable | Emtricitabine, TDF, darunavir, cobicistat |
5 | 57 | 24.9 | 410 | 924 | 31 | Undetectable | Emtricitabine, TDF, efavirenz |
6 | 63 | 27.7 | 667 | 553 | 15 | Undetectable | Abacavir, dolutegravir, lamivudine |
7 | 50 | 34.9 | 379 | 498 | 19 | Undetectable | Emtricitabine, TDF, raltegravir |
8 | 58 | 26.1 | 311 | 331 | 21 | Undetectable | Emtricitabine, TDF, elvitegravir, cobicistat |
9 | 57 | 24.6 | 800 | 597 | 13 | Undetectable | Abacavir, dolutegravir, lamivudine |
10 | 58 | 32.1 | 675 | 494 | 13 | Undetectable | Abacavir, dolutegravir, lamivudine |
11 | 54 | 23.9 | 1082 | 1425 | 17 | Undetectable | Lamivudine, abacavir, raltegravir |